This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in


Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • More than half (55%) of people diagnosed with bone sarcoma in England survive their disease for ten years or more (2009-2013)

  • More than 6 in 10 (62%) people diagnosed with bone sarcoma in England survive their disease for five years or more (2009-2013)

  • More than 8 in 10 (83%) people diagnosed with bone sarcoma in England survive their disease for one year or more (2009-2013)

  • Bone sarcoma 10-year survival in England is similar in men and women (2009-2013)

  • Bone sarcoma five-year survival in England in males is highest for those diagnosed at 50-59 years old and in females is highest for those diagnosed at 15-49 years old (2009-2013)

  • More than 7 in 10 people in England diagnosed with bone sarcoma aged 50-59 survive their disease for five years or more, compared with around 4 in 10 people diagnosed aged 70-89 (2009-2013)

Five-year survival for bone sarcoma is highest in younger men and women and decreases with increasing age.

Five-year net survival in men ranges from 71% in 50-59 year-olds to 44% in 70-89 year-olds for patients diagnosed with bone sarcoma in England during 2009-2013. In women, five-year survival ranges from 75% in 15-49 year olds to 38% in 70-89 year olds.

A review states (2):

  • the most important prognostic factor is the presence of metastasis at the time of diagnosis.
    • patients with local disease that responds to multimodal therapy currently have a 5-year survival rate of more than 70%
    • less than 30% of patients presenting with metastases survive for 5 years
    • patients with metastasis limited to the lung have a better prognosis than those with metastasis to the bone or bone marrow
    • in the absence of metastasis, the tumour site constitutes the single most important prognostic factor, with a worse outcome for patients with proximal primary tumours (i.e., in the pelvis and sacrum) than for patients with distal tumours
    • other clinical indicators of unfavourable evolution include a large primary neoplasm, older age at diagnosis (>18 years), and elevated serum lactate dehydrogenase levels.


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.


Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.